Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC

被引：3
|
作者：
Mazieres, J. [1 ]
Novello, S. [2 ]
De Castro, J. [3 ]
Migliorino, M. R. [4 ]
Helland, A. [5 ,6 ]
Dziadziuszko, R. [7 ]
Griesinger, F. [8 ]
Wolf, J. [9 ]
Zeaiter, A. [10 ]
Cardona, A. [10 ]
Balas, B. [10 ]
Karagiannis, T. [11 ,12 ]
Chlistalla, M. [10 ]
Smoljanovic, V. [10 ]
Oh, I. [12 ]
机构：
[1] Toulouse Univ Hosp, Toulouse, France
[2] Univ Turin, Dept Oncol, Turin, Italy
[3] Univ Hosp La Paz, Dept Med Oncol, Madrid, Spain
[4] San Camillo Forlanini Hosp, Dept Lung Dis, Rome, Italy
[5] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
[6] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Oncol, Oslo, Norway
[7] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland
[8] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Oncol, Oldenburg, Germany
[9] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany
[10] F Hoffmann La Roche Ltd, Basel, Switzerland
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Chonnam Natl Univ, Hwasun Hosp, Jeonnam, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Alectinib; chemotherapy; NSCLC;
D O I：
10.1016/j.jtho.2017.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-013
引用
收藏
页码：S1897 / S1897
页数：1
相关论文
共 50 条
  • [21] Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC)
    Bordoni, R.
    Ciardiello, F.
    Von Pawel, J.
    Cortinovis, D.
    He, P.
    Karagiannis, T.
    Ballinger, M.
    Sandler, A.
    Yu, W.
    Felizzi, F.
    Rittmeyer, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1913 - S1914
  • [22] Circulating free DNA as a prognostic biomarker in patients with advanced ALK plus NSCLC treated with alectinib from the global phase III ALEX trial.
    Dziadziuszko, Rafal
    Peters, Solange
    Mok, Tony S. K.
    Camidge, D. Ross
    Noe, Johannes
    Nowicka, Malgorzata
    Bordogna, Walter
    Morcos, Peter N.
    Smoljanovic, Vlatka
    Tsang, Alice
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Alectinib vs crizotinib in treatment-naive ALK plus NSCLC: CNS efficacy results from the ALEX study
    Gadgeel, S.
    Peters, S.
    Mok, T. S. K.
    Shaw, A. T.
    Kim, D-W.
    Ou, S-H. I.
    Perol, M.
    Dziadziuszko, R.
    Ahn, J. S.
    Rosell, R.
    Zeaiter, A.
    Mitry, E.
    Nueesch, E.
    Balas, B.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC
    Mok, T. S. K.
    Shaw, A. T.
    Camidge, R. D.
    Gadgeel, S. M.
    Rosell, R.
    Dziadziuszko, R.
    Kim, D-W.
    Perol, M.
    Ou, S-H.
    Bordogna, W.
    Smoljanovic, V.
    Hilton, M.
    Peters, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 607 - 607
  • [25] Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK plus non-small cell lung cancer (NSCLC)
    Hirsh, Vera
    Blackhall, Fiona Helen
    Kim, Dong-Wan
    Besse, Benjamin
    Nokihara, Hiroshi
    Han, Ji-Youn
    Tassell, Vanessa Roberts
    Reisman, Arlene
    Iyer, Shrividya
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) plus chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).
    Reck, Martin
    Karagiannis, Tom
    Wehler, Thomas
    Shtivelband, Mikhail
    Gonzalez-Larriba, Jose-Luis
    Rothenstein, Jeffrey
    Frueh, Martin
    Deng, Yu
    Lopez-Chavez, Ariel
    Sandler, Alan
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
    Novello, S.
    Mazieres, J.
    Oh, I-J.
    de Castro, J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    Kotb, A.
    Zeaiter, A.
    Cardona, A.
    Balas, B.
    Johannsdottir, H. K.
    Das-Gupta, A.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2018, 29 (06) : 1409 - 1416
  • [28] Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC.
    Peters, Solange
    Mok, Tony S. K.
    Gadgeel, Shirish M.
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong Ignatius
    Shaw, Alice Tsang
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Ruf, Thorsten
    Archer, Venice Rosale
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
    Kim, Dong-Wan
    Gadgeel, Shirish
    Gettinger, Scott N.
    Riely, Gregory J.
    Oxnard, Geoffrey R.
    Mekhail, Tarek
    Schmid, Peter
    Dowlati, Afshin
    Heist, Rebecca S.
    Wozniak, Antoinette J.
    Singh, Jatinder
    Cha, Edward
    Spahn, Jessica
    Ignatius, Sai-Hong
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (08):
  • [30] Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK plus advanced NSCLC (aNSCLC) in the global phase III ALEX study
    Dziadziuszko, R.
    Mok, T. S.
    Camidge, D. R.
    Shaw, A. T.
    Noe, J.
    Nowicka, M.
    Liu, T.
    Mitry, E.
    Peters, S.
    ANNALS OF ONCOLOGY, 2018, 29
12345